Jakob will help guide Persomics current product line to launch, and will be a tremendous asset in further expanding Persomics' platform as a tool for functional genomics research and beyond. (Martin Svensson, CEO)
Waltham, MA (PRWEB) September 26, 2016
Jakob Lovén is an accomplished R&D scientist and entrepreneur with extensive experience in building early-stage therapeutic-based platform companies. He has led efforts to launch and develop a highly diversified set of innovative biotechnology start-ups – spanning across various therapeutic areas and modalities – securing over $200M in funding from the industry’s top venture capital firms.
A co-founder of Relay Therapeutics, Jakob recently led its formation and launch with $57M in financing from Third Rock Ventures, and is currently responsible for managing the Relay’s strategic direction, growth, and partnerships. Prior to this, Jakob was co-inventor and a founding scientist of Syros Pharmaceuticals, an early-stage drug discovery company focused on novel gene regulation science and technologies. At Syros, Jakob established and led the R&D and platform development efforts to support drug discovery initiatives in oncology and non-oncology indications. These initiatives enabled Syros to identify and rapidly advance its first-in-class lead program into the clinic and supported its recent IPO in July 2016.
Jakob is a mentor to several biotech startups in the Boston area and is a Senior Advisor on the Swedish American Chamber of Commerce Life Science Accelerator.
“Jakob brings a visionary mindset to Persomics. He has a deep understanding of both the scientific and technological foundation of the Persomics platform, coupled with a proven ability to build science-based organizations in the U.S. Jakob will help guide Persomics current product line to launch, and will be a tremendous asset in further expanding Persomics' platform as a tool for functional genomics research and beyond.” – Martin Svensson, Persomics CEO
"The power of Persomics' platform lies in its simplicity. Persomics has managed to simplify phenotypic screening by developing user-friendly, highly miniaturized functional genomic assays across many applications. There is great potential in this platform and how the technology can be purposed beyond its current scope. Applications are not necessarily limited to functional genomics – I see a wider opportunity for developing the platform as a general tool for understanding and engineering cell behavior." – Jakob Lovén
Jakob Lovén has joined the Persomics board as of June 1, 2016, and will initially focus on strengthening the long-term strategic planning of the company.
Please see contact info for further inquiries.